Overview and Scope
Chronic myeloid leukemia (CML) treatment refers to the treatment of chronic myeloid leukemia. Cancer of the blood and bone marrow is called chronic myeloid leukemia (CML). It is characterized by the uncontrolled growth of abnormal white blood cells called myeloid cells. These cells are usually responsible for fighting infections and maintaining the body’s immune system.
Sizing and Forecast
The chronic myeloid leukemia (cml) treatment market size has grown strongly in recent years. It will grow from $7.73 billion in 2023 to $8.18 billion in 2024 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increased awareness and early detection, clinical trial outcomes, targeted therapies development, patient advocacy and support groups, healthcare infrastructure development.
The chronic myeloid leukemia (cml) treatment market size is expected to see strong growth in the next few years. It will grow to $10.4 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to personalized medicine approaches, combination therapies, increasing patient access to novel therapies, government policies supporting orphan drugs, rising healthcare expenditure. Major trends in the forecast period include global collaboration in research, telemedicine and remote monitoring, development of next-generation tkis, treatment optimization strategies..
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-cml-treatment-global-market-report
Segmentation & Regional Insights
The chronic myeloid leukemia (cml) treatment market covered in this report is segmented –
1) By Type: Targeted Therapy, Chemotherapy, Radiation Therapy, Splenectomy, Stem Cell Transplant
2) By Drug Type: Tyrosine Kinase Inhibitors, Antimetabolites, Other Drug Types
3) By Application: Hospitals, Clinic, Other Applications
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
North America was the largest region in the chronic myeloid leukemia (CML) treatment market in 2023. The regions covered in the chronic myeloid leukemia (cml) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=12084&type=smp
Major Driver Impacting Market Growth
The rising incidence and prevalence of chronic myeloid leukemia (CML) population is expected to propel the growth of the chronic myeloid leukemia (CML) treatment market going forward. Chronic myeloid leukemia also known as chronic myelogenous leukemia, is a type of cancer that affects the bone marrow and blood. It is characterized by the overproduction of immature white blood cells called myeloid cells. Chronic myeloid leukemia (CML) treatment helps to slow the progression of cancer and stop it from reaching an advanced phase. For instance, in March 2023, according to the American Society of Clinical Oncology, a US-based professional organization representing physicians of all oncology sub-specialties, in the United States, in 2023, around 35,730 persons (19,860 men and 15,870 women) are anticipated to receive a multiple myeloma diagnosis and 12,590 deaths from this illness are anticipated in 2023 (7,000 males and 5,590 women). Therefore, the rising incidence and prevalence of chronic myeloid leukemia (CML) population is driving the growth of the chronic myeloid leukemia (CML) treatment market going forward.
Key Industry Players
Major companies operating in the chronic myeloid leukemia (CML) treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Hospira Inc., Otsuka Pharmaceutical Co. Ltd., Incyte Corporation, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, Lupin Limited, Innovent Biologics Inc., Glenmark Pharmaceuticals Limited, Il-Yang Pharmaceutical Co. Ltd., Accord Healthcare Inc., ARIAD Pharmaceuticals Inc., Stragen Pharma SA, Orca Bio, Bio-Path Holdings Inc.
The chronic myeloid leukemia (cml) treatment market report table of contents includes:
1. Executive Summary
2. Chronic Myeloid Leukemia (CML) Treatment Market Characteristics
3. Chronic Myeloid Leukemia (CML) Treatment Market Trends And Strategies
4. Chronic Myeloid Leukemia (CML) Treatment Market – Macro Economic Scenario
5. Global Chronic Myeloid Leukemia (CML) Treatment Market Size and Growth
.
.
.
31. Chronic Myeloid Leukemia (CML) Treatment Market Other Major And Innovative Companies
32. Global Chronic Myeloid Leukemia (CML) Treatment Market Competitive Benchmarking
33. Global Chronic Myeloid Leukemia (CML) Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Chronic Myeloid Leukemia (CML) Treatment Market
35. Chronic Myeloid Leukemia (CML) Treatment Market Future Outlook and Potential Analysis
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
